These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 12474153

  • 1. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
    Seehofer D, Rayes N, Tullius SG, Schmidt CA, Neumann UP, Radke C, Settmacher U, Müller AR, Steinmüller T, Neuhaus P.
    Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up.
    Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P.
    Transplantation; 2004 Jan 27; 77(2):226-31. PubMed ID: 14742986
    [Abstract] [Full Text] [Related]

  • 3. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep 27; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 4. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D, Rayes N, Neumann UP, Meisel H, Oettle H, Nüssler NC, Jonas S, Langrehr JM, Neuhaus P.
    Transpl Int; 2005 Aug 27; 18(8):941-8. PubMed ID: 16008744
    [Abstract] [Full Text] [Related]

  • 5. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins.
    Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H.
    Hepatology; 1996 Feb 27; 23(2):240-8. PubMed ID: 8591847
    [Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
    Perrella A, Esposito C, Ioia G, Campanella L, Taglialatela D, Cuomo O.
    Transplant Proc; 2010 May 27; 42(4):1226-8. PubMed ID: 20534267
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 8. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
    Lianghui G, Shusen Z, Tingbo L, Yan S, Weilling W, Anwei L.
    Transplant Proc; 2004 Jun 27; 36(5):1502-5. PubMed ID: 15251371
    [Abstract] [Full Text] [Related]

  • 9. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR.
    Liver Transpl; 2002 Apr 27; 8(4):362-9. PubMed ID: 11965581
    [Abstract] [Full Text] [Related]

  • 10. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP, Campbell AL, Shust GF, Kahn AR, Wistinghausen B, Posada R, Kerkar N, Shneider BL, Emre S, Herold BC.
    Transplantation; 2009 May 15; 87(9):1318-24. PubMed ID: 19424031
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N, Seehofer D, Kahl A, Kokott S, Pratschke J, Frei U, Neuhaus P.
    Transpl Int; 2007 Nov 15; 20(11):974-81. PubMed ID: 17680782
    [Abstract] [Full Text] [Related]

  • 12. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P, Weppler D, Morris MI, Russo C, Nishida S, Levi DM, Moon J, Tekin A, Selvaggi G, Island E, Arosemena L, Ruiz P, Tzakis AG.
    Transplantation; 2011 Nov 15; 92(9):1051-7. PubMed ID: 21876474
    [Abstract] [Full Text] [Related]

  • 13. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR.
    Liver Transpl; 2005 Dec 15; 11(12):1597-602. PubMed ID: 16315314
    [Abstract] [Full Text] [Related]

  • 14. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V.
    Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451
    [Abstract] [Full Text] [Related]

  • 15. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P, Dvornik S, Husnjak SC, Aralica M, Orlić L, Zivcić-Cosić S, Sladoje-Martinović B, Fućak M.
    Acta Med Croatica; 2003 Feb 15; 57(1):49-52. PubMed ID: 12876863
    [Abstract] [Full Text] [Related]

  • 16. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J.
    Transplantation; 2003 Apr 15; 75(7):1020-5. PubMed ID: 12698091
    [Abstract] [Full Text] [Related]

  • 17. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J, Morales-Buenrostro LE, Correa-Rotter R, Muñoz-Trejo T, Zúñiga-Varga J, Cuéllar-González JV, Mayorga-Madrigal H, Vanegas-Carrero R, Aranda F, Rodríguez-Romo R, Herrera-Garcia C, González-Michaca L, Sierra-Madero JG.
    Rev Invest Clin; 2008 Apr 15; 60(5):365-74. PubMed ID: 19227433
    [Abstract] [Full Text] [Related]

  • 18. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS, Romano G, Mastroianni C, Roberta C, Della Corte A, Amarelli C, Maiello C, Giannolo B, Marra C, Ragone E, Grimaldi M, Utili R, Scardone M, Cotrufo M.
    Transplant Proc; 2005 Apr 15; 37(6):2684-7. PubMed ID: 16182784
    [Abstract] [Full Text] [Related]

  • 19. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 15; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 20. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
    Basse G, Esposito L, Mengelle C, Kamar N, Ribes D, Lavayssière L, Pillet A, Suc B, Barange K, Rostaing L.
    Transplant Proc; 2006 Sep 15; 38(7):2339-41. PubMed ID: 16980084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.